Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

169.96
Delayed Data
As of Nov 22
 +0.12 / +0.07%
Today’s Change
138.83
Today|||52-Week Range
191.10
+16.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$123.4B

Company Description

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. Its products include aranesp, blincyto, corlanor, enbrel, epogen, imlygic, kyprolis, neulasta, neupogen, nplate, parsab, prolia, repatha, sensipar, vectibix, and xgeva. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Information

Amgen, Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799
P:(805) 447-1000
Investor Relations:
(805) 447-1060

Employees

Shareholders

Mutual fund holders49.09%
Other institutional31.87%
Individual stakeholders0.71%

Top Executives

Robert A. BradwayChairman & Chief Executive Officer
Esteban SantosExecutive Vice President-Operations
David W. MelineExecutive VP, Chief Financial & Accounting Officer
Sean E. HarperExecutive Vice President-Research & Development
Paul R. EisenbergChief Medical Officer & Senior VP-Global Medical